Morgan Stanley began coverage on shares of SI-BONE (NASDAQ:SIBN) in a research report released on Monday morning, MarketBeat reports. The firm issued an overweight rating and a $24.00 price target on the stock.
A number of other brokerages have also recently issued reports on SIBN. JMP Securities assumed coverage on SI-BONE in a report on Monday. They set an outperform rating and a $27.00 price objective for the company. Canaccord Genuity assumed coverage on SI-BONE in a report on Monday. They set a buy rating and a $25.00 price objective for the company.
Shares of NASDAQ:SIBN opened at $17.57 on Monday. SI-BONE has a 12-month low of $17.22 and a 12-month high of $21.96.
SI-BONE Company Profile
SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Further Reading: What is the quiet period?
Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.